HIV-Positive High-Grade Anal Lesions - Healing Genes

HIV-Positive High-Grade Anal Lesions

Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email

VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions

A Phase 2 Evaluation of VGX-3100, a Synthetic DNA Immunotherapy Targeting Human Papillomavirus 16 and 18 E6 and E7 Proteins, for Anal High-Grade Squamous Intraepithelial Lesions (HSIL) in HIV-Positive Individuals

Phase 2


Doctors at several research centers seek patients with human immunodeficiency virus (HIV)-positive high-grade anal lesions to trial a therapeutic DNA vaccine. This vaccine is a loop of selected DNA from the human papilloma virus which is known to cause anal lesions that can become cancerous. The body’s cells uses the genes to produce proteins that prompt the body to attack anal lesions. Additionally, these conditions are eligible:

  • Anal Intraepithelial Neoplasia
  • High Grade Squamous Intraepithelial Neoplasia
  • HIV Positivity
  • Human Papillomavirus-16 Positive
  • Human Papillomavirus-18 Positive

Study participants will receive intramuscular injections 4 times over 24 weeks, along with a therapy that causes the muscle cells to better absorb the vaccine. Follow up will last up to 48 weeks.


  • Be 27 years of age or older
  • Not be pregnant or breastfeeding
  • Biopsy-proven anal HSIL at screening visit
  • At least one focus of HSIL must be large enough to be monitored for response and not completely removed after the screening biopsy
  • Must be positive for HPV-16 or -18 on genotyping performed on screening anal swab


  1. Screening to confirm acceptance to the study.
  2. Intramuscular injection of the therapy or placebo, with CELLECTRA™-5PSP electric muscle stimulation to enhance absorption of the vaccine
  3. Repeat of step (2) at 4 weeks, 12 weeks, and 24 weeks
  4. A portion of participants will also apply a topical cream 3 times per week for 20 weeks.
  5. Follow up with lab and physical assessments for up to 48 weeks.


The study location is at the University of California, San Francisco, CA. (Map)

Contact: Chia-Ching (Jackie) Wang  |  415-476-4082 ext 146  |  [email protected]



AIDS Malignancy Consortium

National Cancer Institute (NCI)

The EMMES Corporation

University of Arkansas

University of California, Los Angeles

AIDS and Cancer Specimen Resource

Inovio Pharmaceuticals


Or go online:

Subscribe To Our Newsletter

Get updates and learn from the best

More To Explore

Vanquishing the Virus: 160+ COVID-19 Drug and Vaccine Candidates in Development

While President Trump continues to promote antimalarial drugs such as hydroxychloroquine sulfate and azithromycin to treat COVID-19—“What do you have to lose?” he exclaimed during the April 4 Coronavirus Task Force Briefing—the global community of drug discovery researchers and biopharmas is developing a much broader